Acta Med. 2003, 46: 85-89

https://doi.org/10.14712/18059694.2019.12

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)

Ladislav Chrobák, Jaroslava Voglová

Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové, 2nd Department of Medicine, Division of Clinical Hematology, Hradec Králové, Czech Republic

Received April 1, 2003
Accepted May 1, 2003

Crossref Cited-by Linking

  • Yang Fuhua, Wang Ping, Wan Jia, Jia Xiaoqing, Zhou An, Zhang Yuan, Song Jiani, Gong Qiang, Li Wei-Dong, Chen Jieping: Clonal evolution analyses of a chronic myeloid leukemia patient with hematopoietic stem cell transplantation based on deep sequencing. Holist Integ Oncol 2023, 2. <https://doi.org/10.1007/s44178-023-00029-w>
  • Gu Jing Jin, Santiago Lalaine, Mitchell Beverly S.: Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. Blood 2005, 105, 3270. <https://doi.org/10.1182/blood-2004-10-3864>
  • International Swiss MedLab 2004 and 8th Alps Adria Congress / Laboratory Medicine: From Atomic absorption to Zeta-Globin Lucerne, Switzerland, October 5–9, 2004. Clinical Chemistry and Laboratory Medicine (CCLM) 2004, 42. <https://doi.org/10.1515/cclm.2004.42.9.A61>
Crossref Cited-by Linking logo